Lanreotide

1.Overview

Lanreotide is a synthetic analog of the endogenous hormone somatostatin. By mimicking the inhibitory actions of native somatostatin, it provides a therapeutic approach to conditions characterized by hormonal hypersecretion or abnormal cellular proliferation. Its development has focused on improving the pharmacokinetic profile of somatostatin, allowing for more convenient administration compared to the short half-life of the natural peptide.

2.Mechanism of Action

The therapeutic efficacy of lanreotide is mediated through its interaction with somatostatin receptors (SSTRs). While it exhibits affinity for multiple SSTR subtypes, its clinical activity is primarily attributed to its high affinity for SSTR2 and SSTR5. Activation of these receptors leads to the inhibition of adenylate cyclase, reduction of intracellular calcium, and subsequent suppression of hormone release from endocrine and neuroendocrine cells.

3.Why Researchers Study It

Research into lanreotide extends beyond its established use in acromegaly and neuroendocrine tumors. Investigators have explored its potential in managing autosomal dominant polycystic kidney disease (ADPKD), where it has shown promise in reducing liver and kidney volume. Additionally, its role in modulating growth factors like IGF-1 continues to be a subject of interest in various oncological models.

4.Pharmacology & Molecular Identity

Lanreotide is available in different formulations, including microparticle and aqueous autogel preparations, which facilitate sustained release. Pharmacokinetic studies indicate that steady-state concentrations are achieved following repeated administration. It is primarily metabolized and cleared, though specific pathways are complex. It is known to potentially influence the metabolic clearance of other compounds metabolized by cytochrome P450 enzymes.

5.Human Research Evidence

Clinical evidence for lanreotide is well-documented in the treatment of acromegaly, where it effectively reduces GH and IGF-1 levels. In the context of enteropancreatic neuroendocrine tumors, trials have demonstrated its efficacy in controlling symptoms and, in some cases, stabilizing disease progression. Further studies have evaluated its utility in managing carcinoid syndrome, showing significant reduction in the need for rescue medications.

6.Preclinical Research

Preclinical studies have utilized various tumor models to assess the anti-proliferative potential of lanreotide. Research in rat prostate tumor models suggested efficacy comparable to castration, potentially mediated by the reduction of growth factors such as IGF-1. These studies provide a foundational understanding of its inhibitory effects on cell proliferation and hormonal signaling pathways.

7.Safety & Research Limitations

While generally well-tolerated, lanreotide therapy is associated with gastrointestinal side effects, including abdominal discomfort and changes in bowel habits. Because it inhibits insulin and glucagon secretion, patients may experience alterations in glucose homeostasis. Clinical data indicates that safety profiles are consistent across established indications, though long-term monitoring is standard practice in clinical settings.

8.Evidence Quality & Research Gaps

Despite extensive study, the full extent of lanreotide's anti-tumor mechanisms remains an area of active investigation. There is a need for more definitive data regarding its long-term impact on overall survival in various cancer types. Additionally, while its effects on polycystic disease are documented, further large-scale trials are required to establish its role as a standard therapeutic intervention in that population.

9.Frequently Asked Questions

10.References

1. 1.Authors not listed. Lanreotide. . 2012.PMID: 31643689
2. 2.Authors not listed. Lanreotide. . 2006.PMID: 31145576
3. 3.Caplin ME, Pavel M, Ćwikła JB, Phan AT, Raderer M. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. The New England journal of medicine. 2014 Jul 17. DOI: 10.1056/NEJMoa1316158.PMID: 25014687
4. 4.Menon G, Pandit S, Bhusal K. Carcinoid Syndrome. . 2025 Jan.PMID: 28846309
5. 5.Caplin ME, Pavel M, Phan AT, Ćwikła JB, Sedláčková E. Lanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study. Endocrine. 2021 Feb. DOI: 10.1007/s12020-020-02475-2.PMID: 33052555
6. 6.Pusceddu S, Buzzoni R, de Braud F. The underestimated role of somatostatin analogs in the NETTER-1 trial. Future oncology (London, England). 2017 Jun. DOI: 10.2217/fon-2017-0130.PMID: 28492350
7. 7.Godara A, Siddiqui NS, Byrne MM, Saif MW. The safety of lanreotide for neuroendocrine tumor. Expert opinion on drug safety. 2019 Jan. DOI: 10.1080/14740338.2019.1559294.PMID: 30582380
8. 8.Gadelha MR, Bronstein MD, Brue T, Coculescu M, Fleseriu M. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. The lancet. Diabetes & endocrinology. 2014 Nov. DOI: 10.1016/S2213-8587(14)70169-X.PMID: 25260838
9. 9.McLaren DS, Murray RD. Paltusotine, a Novel Oral Somatostatin Receptor Ligand in the Management of Acromegaly. The Journal of clinical endocrinology and metabolism. 2023 Apr 13. DOI: 10.1210/clinem/dgac762.PMID: 36582134
10. 10.Cuff H, Lord K, Ballester L, Scully T, Stewart N. The Use of Lanreotide in the Treatment of Congenital Hyperinsulinism. The Journal of clinical endocrinology and metabolism. 2022 Jul 14. DOI: 10.1210/clinem/dgac322.PMID: 35587448